Yongkun Wei, M.D., Ph.D.

Peer-Reviewed Articles

1. Wei Y, Liu M, Yen EY, Yao J, Xun Z, Nguyen PT, Wang X, Yang Z, Yousef A, Pan D, Jin Y, Li CF, Theardy MS, Park J, Cai Y, Takeda M, Vasquez M, Park EM, Peng DH, Zhou Y, Zhao H, Heffernan TP, Viale A, Wang H, Watowich SS, Liang H, Zhao D, DePinho R, Yao W, Ying H. KRAS Inhibition Activates an Actionable CD24 “Do Not Eat Me” Signal in Pancreatic Cancer. Cancer Res 85(23):4825-4838, 2025. e-Pub 2025. PMID: 40966362.
2. Theardy MS, Takeda M, Sorokin A, Chen S, Yang Z, Wang X, Kanikarla P, Coker O, Nguyen P, Wei Y, Yao J, Yan L, Jin Y, Cai Y, Paku M, Chen Z, Li KZ, Citron F, Tomihara H, Gao S, Deem AK, Zhao J, Wang H, Hanash S, DePinho RA, Maitra A, Draetta GF, Ying H, Kopetz S, Yao W. Therapeutic targeting of syndecan-1 axis overcomes acquired resistance to KRAS-targeted therapy in gastrointestinal cancers. Cell Rep Med 6(8):102253, 2025. e-Pub 2025. PMID: 40713971.
3. Chen MK, Yamaguchi H, Gao Y, Xia W, Chang JT, Hsiao YC, Shegute TW, Lin ZS, Wu CS, Wang YH, Litton JK, Ding Q, Wei Y, Chu YY, Meric-Bernstam F, Piwnica-Worms H, Arun B, Ahnert JR, Liu J, Yao J, Chang WC, Wang HL, Tapia C, Albarracin CT, Keyomarsi K, Wang SC, Wang YN, Hortobagyi GH, Lin C, Yang L, Yu D, Hung MC. FGFR3-induced Y158 PARP1 phosphorylation promotes PARP-inhibitor resistance via BRG1/MRE11-mediated DNA repair in breast cancer models. J Clin Invest 135(14), 2025. e-Pub 2025. PMID: 40460005.
4. Saito Y, Xiao Y, Yao J, Li Y, Liu W, Yuzhalin AE, Shyu YM, Li H, Yuan X, Li P, Zhang Q, Li Z, Wei Y, Yin X, Zhao J, Kariminia SM, Wu YC, Wang J, Yang J, Xia W, Sun Y, Jho EH, Chiao PJ, Hwang RF, Ying H, Wang H, Zhao Z, Maitra A, Hung MC, DePinho RA, Yu D. Targeting a chemo-induced adaptive signaling circuit confers therapeutic vulnerabilities in pancreatic cancer. Cell Discov 10(1):109, 2024. e-Pub 2024. PMID: 39468013.
5. Li CF, Bai LY, Wei Y, Lee HH, Yang R, Yao J, Wang H, Wang YN, Chang WC, Shen YC, Wang SC, Chou CW, Fu J, Ling J, Chu YY, Chiu CF, Wang M, Yu D, Chiao PJ, Liang H, Maitra A, Ying H, Hung MC. All-trans retinoic acid-mediated ADAR1 degradation synergizes with PD-1 blockade to suppress pancreatic cancer. bioRxiv, 2024. e-Pub 2024. PMID: 39484589.
6. Yuzhalin AE, Lowery FJ, Saito Y, Yuan X, Yao J, Duan Y, Ding J, Acharya S, Zhang C, Fajardo A, Chen HN, Wei Y, Sun Y, Zhang L, Xiao Y, Li P, Lorenzi PL, Huse JT, Fan H, Zhao Z, Hung MC, Yu D. Astrocyte-induced Cdk5 expedites breast cancer brain metastasis by suppressing MHC-I expression to evade immune recognition. Nat Cell Biol 26(10):1773-1789, 2024. e-Pub 2024. PMID: 39304713.
7. Takeda M, Theardy MS, Sorokin A, Coker O, Kanikarla P, Chen S, Yang Z, Nguyen P, Wei Y, Yao J, Wang X, Yan L, Jin Y, Cai Y, Paku M, Chen Z, Li KZ, Citron F, Tomihara H, Gao S, Deem AK, Zhao J, Wang H, Hanash S, DePinho RA, Maitra A, Draetta GF, Ying H, Kopetz S, Yao W. Therapeutic targeting of Syndecan-1 axis overcomes acquired resistance to KRAS-targeted therapy in gastrointestinal cancers. bioRxiv, 2024. e-Pub 2024. PMID: 39211217.
8. Wei Y, Liu M, Yen EY, Yao J, Nguyen PT, Wang X, Yang Z, Yousef A, Pan D, Jin Y, Theady MS, Park J, Cai Y, Takeda M, Vasquez M, Zhou Y, Zhao H, Viale A, Wang H, Zhao D, DePinho RA, Yao W, Ying H. KRAS inhibition activates an actionable CD24 'don't eat me' signal in pancreas cancer. bioRxiv, 2023. e-Pub 2023. PMID: 37790498.
9. Nie L, Wang YN, Hsu JM, Hou J, Chu YY, Chan LC, Huo L, Wei Y, Deng R, Tang J, Hsu YH, Ko HW, Lim SO, Huang K, Chen MK, Chiu TJ, Cheng CC, Fang YF, Li CW, Goverdhan A, Wu HJ, Lee CC, Wang WL, Hsu J, Chiao P, Wang SC, Hung MC. Nuclear export signal mutation of epidermal growth factor receptor enhances malignant phenotypes of cancer cells. Am J Cancer Res 13(4):1209-1239, 2023. e-Pub 2023. PMID: 37168336.
10. Xia X, Ye Z, Ahmad S, Wei Y, Yu Y. Editorial: Drug-induced immunogenic cell death patterns and anti-cancer treatment. Front Pharmacol 14:1252168, 2023. e-Pub 2023. PMID: 37521475.
11. Chu YY, Chen MK, Wei Y, Lee HH, Xia W, Wang YN, Yam C, Hsu JL, Wang HL, Chang WC, Yamaguchi H, Jiang Z, Liu C, Li CF, Nie L, Chan LC, Gao Y, Wang SC, Liu J, Westin SN, Lee S, Sood AK, Yang L, Hortobagyi GN, Yu D, Hung MC. Targeting the ALK-CDK9-Tyr19 kinase cascade sensitizes ovarian and breast tumors to PARP inhibition via destabilization of the P-TEFb complex. Nat Cancer 3(10):1211-1227, 2022. e-Pub 2022. PMID: 36253486.
12. Zhao X, Wei Y, Chu YY, Li Y, Hsu JM, Jiang Z, Liu C, Hsu JL, Chang WC, Yang R, Chan LC, Qu J, Zhang S, Ying H, Yu D, Hung MC. Phosphorylation and Stabilization of PD-L1 by CK2 Suppresses Dendritic Cell Function. Cancer Res 82(11):2185-2195, 2022. e-Pub 2022. PMID: 35385574.
13. Wang YN, Lee HH, Wei Y, Chu YY, Xia W, Wang M, Yu D, Hung MC. An optimized protocol for PD-L1 pathological assessment with patient sample deglycosylation to improve correlation with therapeutic response. STAR Protoc 3(1):101198, 2022. e-Pub 2022. PMID: 35243381.
14. Qiu Y, Yang Y, Yang R, Liu C, Hsu JM, Jiang Z, Sun L, Wei Y, Li CW, Yu D, Zhang J, Hung MC. Activated T cell-derived exosomal PD-1 attenuates PD-L1-induced immune dysfunction in triple-negative breast cancer. Oncogene 40(31):4992-5001, 2021. e-Pub 2021. PMID: 34172932.
15. Lee HH, Wang YN, Yang WH, Xia W, Wei Y, Chan LC, Wang YH, Jiang Z, Xu S, Yao J, Qiu Y, Hsu YH, Hwang WL, Yan M, Cha JH, Hsu JL, Shen J, Ye Y, Wu X, Hou MF, Tseng LM, Wang SC, Pan MR, Yang CH, Wang YL, Yamaguchi H, Pang D, Hortobagyi GN, Yu D, Hung MC. Human ribonuclease 1 serves as a secretory ligand of ephrin A4 receptor and induces breast tumor initiation. Nat Commun 12(1):2788, 2021. e-Pub 2021. PMID: 33986289.
16. Jiang Z, Lim SO, Yan M, Hsu JL, Yao J, Wei Y, Chang SS, Yamaguchi H, Lee HH, Ke B, Hsu JM, Chan LC, Hortobagyi GN, Yang L, Lin C, Yu D, Hung MC. TYRO3 induces anti-PD-1/PD-L1 therapy resistance by limiting innate immunity and tumoral ferroptosis. J Clin Invest 131(8), 2021. e-Pub 2021. PMID: 33855973.
17. Zhang L, Yao J, Wei Y, Zhou Z, Li P, Qu J, Badu-Nkansah A, Yuan X, Huang YW, Fukumura K, Mao X, Chang WC, Saunus J, Lakhani S, Huse JT, Hung MC, Yu D. Blocking immunosuppressive neutrophils deters pY696-EZH2-driven brain metastases. Sci Transl Med 12(545), 2020. e-Pub 2020. PMID: 32461334.
18. Xu D, Wang Z, Xia Y, Shao F, Xia W, Wei Y, Li X, Qian X, Lee JH, Du L, Zheng Y, Lv G, Leu JS, Wang H, Xing D, Liang T, Hung MC, Lu Z. The gluconeogenic enzyme PCK1 phosphorylates INSIG1/2 for lipogenesis. Nature 580(7804):530-535, 2020. e-Pub 2020. PMID: 32322062.
19. Han Y, Wei Y, Yao J, Chu YY, Li CW, Hsu JL, Nie L, Hung MC. Inhibition of CDK2 reduces EZH2 phosphorylation and reactivates ERα expression in high-grade serous ovarian carcinoma. Am J Cancer Res 10(4):1194-1206, 2020. e-Pub 2020. PMID: 32368395.
20. Chu YY, Yam C, Chen MK, Chan LC, Xiao M, Wei YK, Yamaguchi H, Lee PC, Han Y, Nie L, Sun X, Moulder SL, Hess KR, Wang B, Hsu JL, Hortobagyi GN, Litton J, Chang JT, Hung MC. Blocking c-Met and EGFR reverses acquired resistance of PARP inhibitors in triple-negative breast cancer. Am J Cancer Res 10(2):648-661, 2020. e-Pub 2020. PMID: 32195033.
21. Nie L, Wei Y, Zhang F, Hsu YH, Chan LC, Xia W, Ke B, Zhu C, Deng R, Tang J, Yao J, Chu YY, Zhao X, Han Y, Hou J, Huo L, Ko HW, Lin WC, Yamaguchi H, Hsu JM, Yang Y, Pan DN, Hsu JL, Kleer CG, Davidson NE, Hortobagyi GN, Hung MC. CDK2-mediated site-specific phosphorylation of EZH2 drives and maintains triple-negative breast cancer. Nat Commun 10(1):5114, 2019. e-Pub 2019. PMID: 31704972.
22. Lee HH, Wang YN, Xia W, Chen CH, Rau KM, Ye L, Wei Y, Chou CK, Wang SC, Yan M, Tu CY, Hsia TC, Chiang SF, Chao KSC, Wistuba II, Hsu JL, Hortobagyi GN, Hung MC. Removal of N-Linked Glycosylation Enhances PD-L1 Detection and Predicts Anti-PD-1/PD-L1 Therapeutic Efficacy. Cancer Cell 36(2):168-178.e4, 2019. e-Pub 2019. PMID: 31327656.
23. Chan LC, Li CW, Xia W, Hsu JM, Lee HH, Cha JH, Wang HL, Yang WH, Yen EY, Chang WC, Zha Z, Lim SO, Lai YJ, Liu C, Liu J, Dong Q, Yang Y, Sun L, Wei Y, Nie L, Hsu JL, Li H, Ye Q, Hassan MM, Amin HM, Kaseb AO, Lin X, Wang SC, Hung MC. IL-6/JAK1 pathway drives PD-L1 Y112 phosphorylation to promote cancer immune evasion. J Clin Invest 129(8):3324-3338, 2019. e-Pub 2019. PMID: 31305264.
24. Dong Q, Du Y, Li H, Liu C, Wei Y, Chen MK, Zhao X, Chu YY, Qiu Y, Qin L, Yamaguchi H, Hung MC. EGFR and c-MET Cooperate to Enhance Resistance to PARP Inhibitors in Hepatocellular Carcinoma. Cancer Res 79(4):819-829, 2019. e-Pub 2019. PMID: 30573522.
25. Yang Y, Hsu JM, Sun L, Chan LC, Li CW, Hsu JL, Wei Y, Xia W, Hou J, Qiu Y, Hung MC. Palmitoylation stabilizes PD-L1 to promote breast tumor growth. Cell Res 29(1):83-86, 2019. e-Pub 2019. PMID: 30514902.
26. Lee PC, Fang YF, Yamaguchi H, Wang WJ, Chen TC, Hong X, Ke B, Xia W, Wei Y, Zha Z, Wang Y, Kuo HP, Wang CW, Tu CY, Chen CH, Huang WC, Chiang SF, Nie L, Hou J, Chen CT, Huo L, Yang WH, Deng R, Nakai K, Hsu YH, Chang SS, Chiu TJ, Tang J, Zhang R, Wang L, Fang B, Chen T, Wong KK, Hsu JL, Hung MC. Targeting PKCδ as a Therapeutic Strategy against Heterogeneous Mechanisms of EGFR Inhibitor Resistance in EGFR-Mutant Lung Cancer. Cancer Cell 34(6):954-969.e4, 2018. e-Pub 2018. PMID: 30537515.
27. Chou CK, Huang PJ, Tsou PH, Wei Y, Lee HH, Wang YN, Liu YL, Shi C, Yeh HC, Kameoka J, Hung MC. A flow-proteometric platform for analyzing protein concentration (FAP): Proof of concept for quantification of PD-L1 protein in cells and tissues. Biosens Bioelectron 117:97-103, 2018. e-Pub 2018. PMID: 29890396.
28. Zhang Y, Shi J, Liu X, Feng L, Gong Z, Koppula P, Sirohi K, Li X, Wei Y, Lee H, Zhuang L, Chen G, Xiao ZD, Hung MC, Chen J, Huang P, Li W, Gan B. BAP1 links metabolic regulation of ferroptosis to tumour suppression. Nat Cell Biol 20(10):1181-1192, 2018. e-Pub 2018. PMID: 30202049.
29. Cha JH, Yang WH, Xia W, Wei Y, Chan LC, Lim SO, Li CW, Kim T, Chang SS, Lee HH, Hsu JL, Wang HL, Kuo CW, Chang WC, Hadad S, Purdie CA, McCoy AM, Cai S, Tu Y, Litton JK, Mittendorf EA, Moulder SL, Symmans WF, Thompson AM, Piwnica-Worms H, Chen CH, Khoo KH, Hung MC. Metformin Promotes Antitumor Immunity via Endoplasmic-Reticulum-Associated Degradation of PD-L1. Mol Cell 71(4):606-620.e7, 2018. e-Pub 2018. PMID: 30118680.
30. Yang Y, Li CW, Chan LC, Wei Y, Hsu JM, Xia W, Cha JH, Hou J, Hsu JL, Sun L, Hung MC. Exosomal PD-L1 harbors active defense function to suppress T cell killing of breast cancer cells and promote tumor growth. Cell Res 28(8):862-864, 2018. e-Pub 2018. PMID: 29959401.
31. Peng JM, Bera R, Chiou CY, Yu MC, Chen TC, Chen CW, Wang TR, Chiang WL, Chai SP, Wei Y, Wang H, Hung MC, Hsieh SY. Actin cytoskeleton remodeling drives epithelial-mesenchymal transition for hepatoma invasion and metastasis in mice. Hepatology 67(6):2226-2243, 2018. e-Pub 2018. PMID: 29171033.
32. Zhang P, Xiao Z, Wang S, Zhang M, Wei Y, Hang Q, Kim J, Yao F, Rodriguez-Aguayo C, Ton BN, Lee M, Wang Y, Zhou Z, Zeng L, Hu X, Lawhon SE, Siverly AN, Su X, Li J, Xie X, Cheng X, Liu LC, Chang HW, Chiang SF, Lopez-Berestein G, Sood AK, Chen J, You MJ, Sun SC, Liang H, Huang Y, Yang X, Sun D, Sun Y, Hung MC, Ma L. ZRANB1 Is an EZH2 Deubiquitinase and a Potential Therapeutic Target in Breast Cancer. Cell Rep 23(3):823-837, 2018. e-Pub 2018. PMID: 29669287.
33. Wang YN, Lee HH, Chou CK, Yang WH, Wei Y, Chen CT, Yao J, Hsu JL, Zhu C, Ying H, Ye Y, Wang WJ, Lim SO, Xia W, Ko HW, Liu X, Liu CG, Wu X, Wang H, Li D, Prakash LR, Katz MH, Kang Y, Kim M, Fleming JB, Fogelman D, Javle M, Maitra A, Hung MC. Angiogenin/Ribonuclease 5 Is an EGFR Ligand and a Serum Biomarker for Erlotinib Sensitivity in Pancreatic Cancer. Cancer Cell 33(4):752-769.e8, 2018. e-Pub 2018. PMID: 29606349.
34. Wan L, Xu K, Wei Y, Zhang J, Han T, Fry C, Zhang Z, Wang YV, Huang L, Yuan M, Xia W, Chang WC, Huang WC, Liu CL, Chang YC, Liu J, Wu Y, Jin VX, Dai X, Guo J, Liu J, Jiang S, Li J, Asara JM, Brown M, Hung MC, Wei W. Phosphorylation of EZH2 by AMPK Suppresses PRC2 Methyltransferase Activity and Oncogenic Function. Mol Cell 69(2):279-291.e5, 2018. e-Pub 2018. PMID: 29351847.
35. Yamaguchi H, Du Y, Nakai K, Ding M, Chang SS, Hsu JL, Yao J, Wei Y, Nie L, Jiao S, Chang WC, Chen CH, Yu Y, Hortobagyi GN, Hung MC. EZH2 contributes to the response to PARP inhibitors through its PARP-mediated poly-ADP ribosylation in breast cancer. Oncogene 37(2):208-217, 2018. e-Pub 2018. PMID: 28925391.
36. Jiao S, Xia W, Yamaguchi H, Wei Y, Chen MK, Hsu JM, Hsu JL, Yu WH, Du Y, Lee HH, Li CW, Chou CK, Lim SO, Chang SS, Litton J, Arun B, Hortobagyi GN, Hung MC. PARP Inhibitor Upregulates PD-L1 Expression and Enhances Cancer-Associated Immunosuppression. Clin Cancer Res 23(14):3711-3720, 2017. e-Pub 2017. PMID: 28167507.
37. Wang Y, Hsu JM, Kang Y, Wei Y, Lee PC, Chang SJ, Hsu YH, Hsu JL, Wang HL, Chang WC, Li CW, Liao HW, Chang SS, Xia W, Ko HW, Chou CK, Fleming JB, Wang H, Hwang RF, Chen Y, Qin J, Hung MC. Oncogenic Functions of Gli1 in Pancreatic Adenocarcinoma Are Supported by Its PRMT1-Mediated Methylation. Cancer Res 76(23):7049-7058, 2016. e-Pub 2016. PMID: 27758883.
38. Ko HW, Lee HH, Huo L, Xia W, Yang CC, Hsu JL, Li LY, Lai CC, Chan LC, Cheng CC, Labaff AM, Liao HW, Lim SO, Li CW, Wei Y, Nie L, Yamaguchi H, Hung MC. GSK3beta inactivation promotes the oncogenic functions of EZH2 and enhances methylation of H3K27 in human breast cancers. Oncotarget 7(35):57131-57144, 2016. e-Pub 2016. PMID: 27494834.
39. Li N, Dhar SS, Chen TY, Kan PY, Wei Y, Kim JH, Chan CH, Lin HK, Hung MC, Lee MG. JARID1D Is a Suppressor and Prognostic Marker of Prostate Cancer Invasion and Metastasis. Cancer Res 76(4):831-43, 2016. e-Pub 2016. PMID: 26747897.
40. Li N, Dhar SS, Chen TY, Kan PY, Wei Y, Kim JH, Chan CH, Lin HK, Hung MC, Lee MG. JARID1D Is a Suppressor and Prognostic Marker of Prostate Cancer Invasion and Metastasis. Cancer Res 76(4):831-843, 2016. e-Pub 2016.
41. Du Y, Yamaguchi H, Wei Y, Hsu JL, Wang HL, Hsu YH, Lin WC, Yu WH, Leonard PG, Lee GR 4th, Chen MK, Nakai K, Hsu MC, Chen CT, Sun Y, Wu Y, Chang WC, Huang WC, Liu CL, Chang YC, Chen CH, Park M, Jones P, Hortobagyi GN, Hung MC. Blocking c-Met-mediated PARP1 phosphorylation enhances anti-tumor effects of PARP inhibitors. Nat Med 22(2):194-201, 2016. e-Pub 2016. PMID: 26779812.
42. Lin A, Li C, Xing Z, Hu Q, Liang K, Han L, Wang C, Hawke DH, Wang S, Zhang Y, Wei Y, Ma G, Park PK, Zhou J, Zhou Y, Hu Z, Zhou Y, Marks JR, Liang H, Hung MC, Lin C, Yang L. The LINK-A lncRNA activates normoxic HIF1alpha signalling in triple-negative breast cancer. Nat Cell Biol 18(2):213-24, 2016. e-Pub 2016. PMID: 26751287.
43. Yang CC, LaBaff A, Wei Y, Nie L, Xia W, Huo L, Yamaguchi H, Hsu YH, Hsu JL, Liu D, Lang J, Du Y, Lien HC, Li LY, Deng R, Chan LC, Yao J, Kleer CG, Hortobagyi GN, Hung MC. Phosphorylation of EZH2 at T416 by CDK2 contributes to the malignancy of triple negative breast cancers. Am J Transl Res 7(6):1009-1020, 2015. e-Pub 2015.
44. Sorokin AV, Nair BC, Wei Y, Aziz KE, Evdokimova V, Hung MC, Chen J. Aberrant Expression of proPTPRN2 in Cancer Cells Confers Resistance to Apoptosis. Cancer Res 75(9):1846-58, 2015. e-Pub 2015. PMID: 25877877.
45. Sorokin AV, Nair BC, Wei Y, Aziz KE, Evdokimova V, Hung MC, Chen J. Aberrant Expression of proPTPRN2 in Cancer Cells Confers Resistance to Apoptosis. Cancer Res 75(9):1846-1858, 2015. e-Pub 2015.
46. Yang CC, LaBaff A, Wei Y, Nie L, Xia W, Huo L, Yamaguchi H, Hsu YH, Hsu JL, Liu D, Lang J, Du Y, Lien HC, Li LY, Deng R, Chan LC, Yao J, Kleer CG, Hortobagyi GN, Hung MC. Phosphorylation of EZH2 at T416 by CDK2 contributes to the malignancy of triple negative breast cancers. Am J Transl Res 7(6):1009-20, 2015. e-Pub 2015. PMID: 26279746.
47. Xing Z, Lin A, Li C, Liang K, Wang S, Liu Y, Park PK, Qin L, Wei Y, Hawke DH, Hung MC, Lin C, Yang L. lncRNA Directs Cooperative Epigenetic Regulation Downstream of Chemokine Signals. Cell 159(5):1110-1125, 2014. e-Pub 2014.
48. Hsu YH, Yao J, Chan LC, Wu TJ, Hsu JL, Fang YF, Wei Y, Wu Y, Huang WC, Liu CL, Chang YC, Wang MY, Li CW, Shen J, Chen MK, Sahin AA, Sood A, Mills GB, Yu D, Hortobagyi GN, Hung MC. Definition of PKC-α, CDK6, and MET as therapeutic targets in triple-negative breast cancer. Cancer Res 74(17):4822-4835, 2014. e-Pub 2014.
49. Zhang P, Wei Y, Wang L, Debeb BG, Yuan Y, Zhang J, Yuan J, Wang M, Chen D, Sun Y, Woodward WA, Liu Y, Dean DC, Liang H, Hu Y, Ang KK, Hung MC, Chen J, Ma L. ATM-mediated stabilization of ZEB1 promotes DNA damage response and radioresistance through CHK1. Nat Cell Biol 16(9):864-875, 2014. e-Pub 2014.
50. Thirumurthi U, Shen J, Xia W, LaBaff AM, Wei Y, Li CW, Chang WC, Chen CH, Lin HK, Yu D, Hung MC. MDM2-mediated degradation of SIRT6 phosphorylated by AKT1 promotes tumorigenesis and trastuzumab resistance in breast cancer. Sci Signal 7(336):ra71, 2014. e-Pub 2014.
51. Khotskaya YB, Goverdhan A, Shen J, Ponz-Sarvise M, Chang SS, Hsu MC, Wei Y, Xia W, Yu D, Hung MC. S6K1 promotes invasiveness of breast cancer cells in a model of metastasis of triple-negative breast cancer. Am J Transl Res 6(4):361-376, 2014. e-Pub 2014.
52. Zhou G, Wang J, Zhao M, Xie TX, Tanaka N, Sano D, Patel AA, Ward AM, Sandulache VC, Jasser SA, Skinner HD, Fitzgerald AL, Osman AA, Wei Y, Xia X, Songyang Z, Mills GB, Hung MC, Caulin C, Liang J, Myers JN. Gain-of-function mutant p53 promotes cell growth and cancer cell metabolism via inhibition of AMPK activation. Mol Cell 54(6):960-974, 2014. e-Pub 2014.
53. Wagner KW, Alam H, Dhar SS, Giri U, Li N, Wei Y, Giri D, Cascone T, Kim JH, Ye Y, Multani AS, Chan CH, Erez B, Saigal B, Chung J, Lin HK, Wu X, Hung MC, Heymach JV, Lee MG. KDM2A promotes lung tumorigenesis by epigenetically enhancing ERK1/2 signaling. J Clin Invest 123(12):5231-46, 2013. e-Pub 2013.
54. Zhang J, Zhang P, Wei Y, Piao HL, Wang W, Maddika S, Wang M, Chen D, Sun Y, Hung MC, Chen J, Ma L. Deubiquitylation and stabilization of PTEN by USP13. Nat Cell Biol 15(12):1486-94, 2013. e-Pub 2013.
55. Huang TH, Huo L, Wang YN, Xia W, Wei Y, Chang SS, Chang WC, Fang YF, Chen CT, Lang JY, Tu C, Wang Y, Hsu MC, Kuo HP, Ko HW, Shen J, Lee HH, Lee PC, Wu Y, Chen CH, Hung MC. Epidermal growth factor receptor potentiates MCM7-mediated DNA replication through tyrosine phosphorylation of Lyn kinase in human cancers. Cancer Cell 23(6):796-810, 2013. e-Pub 2013.
56. Chen D, Sun Y, Wei Y, Zhang P, Rezaeian AH, Teruya-Feldstein J, Gupta S, Liang H, Lin HK, Hung MC, Ma L. LIFR is a breast cancer metastasis suppressor upstream of the Hippo-YAP pathway and a prognostic marker. Nat Med 18(10):1511-7, 2012. e-Pub 2012. PMID: 23001183.
57. Liu M, Lee DF, Chen CT, Yen CJ, Li LY, Lee HJ, Chang CJ, Chang WC, Hsu JM, Kuo HP, Xia W, Wei Y, Chiu PC, Chou CK, Du Y, Dhar D, Karin M, Chen CH, Hung MC. IKKα activation of NOTCH links tumorigenesis via FOXA2 suppression. Mol Cell 45(2):171-84, 2012. e-Pub 2012. PMID: 22196886.